Using biometric sensor data to monitor cancer patients during radiotherapy: Protocol for the OncoWatch feasibility study
Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Standard
Using biometric sensor data to monitor cancer patients during radiotherapy : Protocol for the OncoWatch feasibility study. / Holländer-Mieritz, Cecilie; Vogelius, Ivan R.; Kristensen, Claus A.; Green, Allan; Rindum, Judith L.; Pappot, Helle.
I: JMIR Research Protocols, Bind 10, Nr. 5, e26096, 2021.Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Using biometric sensor data to monitor cancer patients during radiotherapy
T2 - Protocol for the OncoWatch feasibility study
AU - Holländer-Mieritz, Cecilie
AU - Vogelius, Ivan R.
AU - Kristensen, Claus A.
AU - Green, Allan
AU - Rindum, Judith L.
AU - Pappot, Helle
N1 - Publisher Copyright: © Cecilie Holländer-Mieritz, Ivan R Vogelius, Claus A Kristensen, Allan Green, Judith L Rindum, Helle Pappot.
PY - 2021
Y1 - 2021
N2 - Background: Patients with head and neck cancer (HNC) experience severe side effects during radiotherapy (RT). Ongoing technological advances in wearable biometric sensors allow for the collection of objective data (eg, physical activity and heart rate), which might, in the future, help detect and counter side effects before they become severe. A smartwatch such as the Apple Watch allows for objective data monitoring outside the hospital with minimal effort from the patient. To determine whether such tools can be implemented in the oncological setting, feasibility studies are needed. Objective: This protocol describes the design of the OncoWatch 1.0 feasibility study that assesses the adherence of patients with HNC to an Apple Watch during RT. Methods: A prospective, single-cohort trial will be conducted at the Department of Oncology, Rigshospitalet (Copenhagen, Denmark). Patients aged ≥18 years intended for primary or postoperative curatively intended RT for HNC will be recruited. Consenting patients will be asked to wear an Apple Watch on the wrist during and until 2 weeks after RT. The study will include 10 patients. Data on adherence, data acquisition, and biometric data will be collected. Demographic data, objective toxicity scores, and hospitalizations will be documented. Results: The primary outcome is to determine if it is feasible for the patients to wear a smartwatch continuously (minimum 12 hours/day) during RT. Furthermore, we will explore how the heart rate and physical activity change over the treatment course. Conclusions: The study will assess the feasibility of using the Apple Watch for home monitoring of patients with HNC. Our findings may provide novel insights into the patient’s activity levels and variations in heart rate during the treatment course. The knowledge obtained from this study will be essential for further investigating how biometric data can be used as part of symptom monitoring for patients with HNC.
AB - Background: Patients with head and neck cancer (HNC) experience severe side effects during radiotherapy (RT). Ongoing technological advances in wearable biometric sensors allow for the collection of objective data (eg, physical activity and heart rate), which might, in the future, help detect and counter side effects before they become severe. A smartwatch such as the Apple Watch allows for objective data monitoring outside the hospital with minimal effort from the patient. To determine whether such tools can be implemented in the oncological setting, feasibility studies are needed. Objective: This protocol describes the design of the OncoWatch 1.0 feasibility study that assesses the adherence of patients with HNC to an Apple Watch during RT. Methods: A prospective, single-cohort trial will be conducted at the Department of Oncology, Rigshospitalet (Copenhagen, Denmark). Patients aged ≥18 years intended for primary or postoperative curatively intended RT for HNC will be recruited. Consenting patients will be asked to wear an Apple Watch on the wrist during and until 2 weeks after RT. The study will include 10 patients. Data on adherence, data acquisition, and biometric data will be collected. Demographic data, objective toxicity scores, and hospitalizations will be documented. Results: The primary outcome is to determine if it is feasible for the patients to wear a smartwatch continuously (minimum 12 hours/day) during RT. Furthermore, we will explore how the heart rate and physical activity change over the treatment course. Conclusions: The study will assess the feasibility of using the Apple Watch for home monitoring of patients with HNC. Our findings may provide novel insights into the patient’s activity levels and variations in heart rate during the treatment course. The knowledge obtained from this study will be essential for further investigating how biometric data can be used as part of symptom monitoring for patients with HNC.
KW - Biometric sensor technology
KW - Cancer
KW - Head and neck cancer
KW - Home monitoring
KW - Patient-generated health data
KW - Radiotherapy
KW - Sensor
KW - Smartwatch
U2 - 10.2196/26096
DO - 10.2196/26096
M3 - Journal article
C2 - 33983123
AN - SCOPUS:85106248744
VL - 10
JO - J M I R Research Protocols
JF - J M I R Research Protocols
SN - 1929-0748
IS - 5
M1 - e26096
ER -
ID: 301695193